TickerTalks
Browse all tickers →
TickerTalks›$PAYS
PAPAYS

Paysign, Inc.

$PAYS·$752M·Specialty Business Services·Industrials
$13.03+1.2%YTD+149.6%1Y+142.6%
Price updated 22m ago·X counts updated 22h ago
PAPAYS
$PAYSPaysign, Inc.
$13.03+1.16%31 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $PAYS on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

31X posts · last 7 days
Aug 26Sep 8
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $PAYS's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-12

The tone on Paysign is celebratory. A prominent holder recounts tripling in three months after a 25% post-earnings plunge, then reports the latest print beat on every line with a raised guide across the board and expanding incremental margins. Plasma is called out of its industry funk and pharma described as booming. A small-cap screener lists PAYS as a top-seven B- Buy, and the stock is 'popping hard' into the close.

Read what X is saying about $PAYS

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PAYS — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-09

The move is getting stronger, with heavier trading behind it.

Paysign up 150% YTD on 48% Q1 revenue growth — the patient-affordability specialist scaling with BlackRock adding.

Paysign Inc. provides prepaid card payment solutions — the specific rails behind pharma patient-affordability programs (co-pay assistance) and plasma-donor payments. Up 150% YTD on real revenue growth and expanding patient-affordability adoption.

  • Q1 revenue grew 48% YoY to $28M with 17% operating margins and 10% FCF yield — genuinely elite growth-and-profitability for a small-cap, and the analyst FY EPS at $0.30+ supports the 43x TTM P/E as reasonable for the growth.
  • BlackRock added 3.08M shares — a real institutional flow signal at this size that shifts the shareholder base and often precedes further institutional buying at smaller mid-caps.
  • Position at 20% above the 50-day and 93% above the 200-day with volume at 1.44x normal — a fully confirmed acceleration, and the recent 'tripled in three months after a 25% post-earnings plunge' trader account captures the tape math.

The Nov 11 Q3 print at $0.09 estimated EPS is the fundamental test — a beat with continued patient-affordability program adoption and firm plasma-donor volume commentary sustains the acceleration; a specific customer-loss event or plasma-industry slowdown is what turns this from accelerating into a first cooling.

Agrees with X sentimentAgree with the bullish framing — the 48% Q1 revenue growth, BlackRock's 3.08M-share position add, and the raised guide across the board are all real. The $117M revenue target as the patient-affordability business surges is a legitimate FY horizon.

What to watch: The Nov 11 Q3 print at $0.09 estimated EPS — specifically patient-affordability program adoption and plasma volumes. A beat plus firm attach sustains acceleration; a customer loss or plasma slowdown cools the tape.

On the calendar: 2026-11-11 — Q3 2026 earnings

Read the AI verdict on $PAYS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Prepaid debit card and digital banking services company processing payments for patient affordability programs and corporate disbursements.

Industry overviewAI analysisGenerated by AI from underlying data

Where Specialty Business Services sits in its cycle right now — and what that implies for $PAYS.

Specialty Business Services · Industrials

Specialty business-service providers benefit from outsourcing demand and AI-augmented service efficiency; pest control and uniform services are non-cyclical steady compounders. Vehicle-auction and insurance-assessment platforms serve the normalising auto market.

What this means for $PAYS

Neutral — limited data.

Industry benchmark

6-name peer basket
+2.2%YTD
-15.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
43.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
19.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
17.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
9.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
30.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
56.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.11$0.06+83.3%
Q1 2026May 12, 2026$0.09$0.07+28.6%
Q4 2025Mar 24, 2026$0.02$0.020.0%
Q3 2025Nov 12, 2025$0.04$0.03+33.3%
Next earningsWed, Nov 11·consensus EPS $0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$28.3M+48.1%63.3%24.8%$0.12$-1.0M
Q1 FY26$28.0M+50.8%55.6%23.8%$0.10$17.1M
Q4 FY25$22.8M+45.8%48.0%8.1%$0.02$46.4M
Q3 FY25$21.6M+41.6%56.3%7.3%$0.04$4.6M

Forward consensus

2-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$114.7M$112.9M – $116.0M$0.34$0.34 – $0.353
FY27$133.2M$131.1M – $134.8M$0.42$0.41 – $0.433

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.86%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+19.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+93.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 34.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.805-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 12Baker Jeffery BradfordCFO35.0K sh$442KSellAug 6Mark NewcomerCEO150.0K sh$1.8MSellJul 29Mark NewcomerCEO50.0K sh$469KSellJul 16Joan M HermanEVP, Operations28.0K sh$243KSellJul 15Joan M HermanEVP, Operations31.9K sh$274KSellJun 26Joan M HermanEVP, Operations100.0K sh$801KSellJun 11Bruce A MinaDirector10.0K sh$71KSellJun 1Cunningham Bradley KramerCTO3.0K sh$23KSellJun 1Bruce A MinaDirector10.0K sh$71KSellJun 1Joan M HermanEVP, Operations29.2K sh$234K
1–10 of 13
+ 32 other (17 inkinds · 9 exempts · 6 awards) in window

See when $PAYS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsSep 83
3New insider — initial holdingsSep 43
AI summary

Bradley Kramer Cunningham, Chief Technology Officer of Paysign, Inc. (PAYS), filed an initial beneficial ownership statement (Form 3) reporting direct ownership of 374,000 shares of common stock across five tranches (130k, 30k, 114k, 33,334, and 66,666 shares) as of December 14, 2025, though submitted September 2026. No derivative securities are reported. This is a routine Section 16 initial filing for a newly reportable officer; the delayed submission is administrative and carries no trading signal.

3New insider — initial holdingsSep 43
AI summary

Matthew Baker Turner, President of Patient Affordability at Paysign, Inc. (PAYS), filed an initial beneficial ownership statement reporting direct ownership of 236,667 shares of common stock (120,000 and 116,667 share tranches) plus a non-qualified stock option for 15,000 shares at a $3.87 exercise price expiring March 23, 2030, triggered by an August 11, 2025 event. This is a routine Section 16 initial filing for a newly reportable officer; no new purchases or sales are disclosed.

8-KShareholder voteMay 138-K — Item 5.07: Shareholder vote
+ 9 other (3 earnings 8-Ks · 2 10-Qs · 2 proxys · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

BlackRock Inc. Buys Shares of 3,079,208 Paysign, Inc. $PAYSdefenseworld.net·7d agoPaysign Targets $117M Revenue as Patient-Affordability Business Surgesmarketbeat.com·13d agoPaysign (PAYS) is an Incredible Growth Stock: 3 Reasons Whyzacks.com·14d agoPaysign (PAYS) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·14d agoAre Business Services Stocks Lagging Paysign (PAYS) This Year?zacks.com·27d ago

In themes

Explore the broader themes this ticker is being talked about under.

Consumer Fintech & Neobanks

More in Specialty Business Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$CPRT$ANPA$ROL$SPIR$CTAS$TISI
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport